The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | Sequencing CAR-T and novel agents in R/R DLBCL in the current era
In this video, Marek Trněný, MD, Charles University Hospital, Prague, Czech Republic, discusses sequencing of novel therapies for the treatment of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). He highlights that many unanswered questions remain in this area, but that the advent of novel therapies has led to improved survival outcomes for these patients. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Sometimes it’s difficult currently to sequence properly. We do not know a lot of the questions. But we have presented the data at the EHA meeting in Milan, that in the Czech Republic, when we compare two eras, three years until 2020 and three years after 2020, there is a significant improvement for the group of patients who required third line for the relapsed/refractory diffuse large B-cell lymphoma...
Sometimes it’s difficult currently to sequence properly. We do not know a lot of the questions. But we have presented the data at the EHA meeting in Milan, that in the Czech Republic, when we compare two eras, three years until 2020 and three years after 2020, there is a significant improvement for the group of patients who required third line for the relapsed/refractory diffuse large B-cell lymphoma. There is more than 30% risk reduction of the death for those patients who are treated currently. And this is not only the issue of the CAR T-cell. This is the issue of the other novel treatments like the ADCs, polatuzumab vedotin, and loncastuximab, like the monoclonal antibodies. And we have really to learn how to sequence those therapies because we know that, and it’s usual practice, that we use the bispecific antibodies if CAR T-cell therapy fails and there is a 30% or 35% complete remission rate, but sometimes we can find some biomarkers of the exhaustion or lower lymphocyte cell count and maybe it would be better to use the ADCs etc. There is a lot of the open questions we have to learn, but this is really fascinating era and this is good for our patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
